APA (7th ed.) Citation

Trogen, B., & Sicherer, S. (2023). As-Needed Use of Short-Acting β2-Agonists Alone Versus As-Needed Use of Short-acting β2-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis. Pediatrics (Evanston), 152(Supplement 3), S52-S53. https://doi.org/10.1542/peds.2023-064344NA

Chicago Style (17th ed.) Citation

Trogen, Brit, and Scott Sicherer. "As-Needed Use of Short-Acting β2-Agonists Alone Versus As-Needed Use of Short-acting β2-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis." Pediatrics (Evanston) 152, no. Supplement 3 (2023): S52-S53. https://doi.org/10.1542/peds.2023-064344NA.

MLA (9th ed.) Citation

Trogen, Brit, and Scott Sicherer. "As-Needed Use of Short-Acting β2-Agonists Alone Versus As-Needed Use of Short-acting β2-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis." Pediatrics (Evanston), vol. 152, no. Supplement 3, 2023, pp. S52-S53, https://doi.org/10.1542/peds.2023-064344NA.